Skip to main content
. 2023 Feb 1;15(3):933. doi: 10.3390/cancers15030933

Figure 3.

Figure 3

Immunomodulatory properties of BRAF/MEK inhibitors affecting ILC2s. BRAF/MEK inhibitors limit tumor infiltration of MDSCs and Tregs, which may dampen ILC activation through cell–cell contact and suppressive cytokines, such as TGF-β and IL-10 (A, B). Moreover, targeted therapy directly down-regulates IL-10 secretion by melanoma cells (C). Altogether, these phenomena would contribute to the ILC2-mediated infiltration of anti-melanoma eosinophils (D).